NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









TATUM Bioscience

TATUM Bioscience

Private
SherbrookeHealthcare & Life Scienceshttps://www.tatumbio.com/

Last Round

Grant

Jun 18, 2026

Total Funding Raised

$5.8M

Company Overview

TATUM Bioscience is a biotechnology company that develops next-generation immunotherapies using a proprietary synthetic biology platform to create multimodal nanofilaments for cancer treatment.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

immunotherapybiotechnologynanofilamentcancer treatmentcancer immunotherapysynthetic biologyimmuno-oncologycheckpoint inhibitoroncologydrug discoverybiologicsantitumor vaccinenext-gen biologicsprecision medicinepreclinical research

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

TATUM Bioscience Comparables

Compare TATUM Bioscience with similar companies based on industry and business-model similarity.

TATUM Bioscience comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Baccine Ltd.
80%
Sebastian BioPharma
73%
Theraphage
73%

TATUM Bioscience Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 18, 2026
SeedSep 1, 2025
AcceleratorApr 10, 2025
AcceleratorMay 21, 2024
AcceleratorJun 30, 2022

Key People

Founding team and executive leadership

Jean-François Millau

Co-founder & CEO

Founding Team

TATUM Bioscience Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 30, 2022

    Fundraising round completed with Creative Destruction Lab.

TATUM Bioscience Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

TATUM Bioscience Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about TATUM Bioscience's valuation, stock price, and market status.

Firmographic Details

HeadquartersSherbrooke
Employee Range8
Year Founded2021
Last FundingJun 18, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.